Corneal safety of topically applied naltrexone

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 5, 2006, Pages 377-387

  Zagon, Ian S ^a,b   Klocek, Matthew S ^a   Sassani, Joseph W ^a   Mauger, David T ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; NALTREXONE; OPIATE ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL DEATH; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA SENSIBILITY; CORNEA THICKNESS; DOSE RESPONSE; DRUG SAFETY; ENDOTHELIUM CELL; EPITHELIUM CELL; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR PRESSURE; LONG TERM EXPOSURE; MALE; NONHUMAN; RAT; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANIMALS; APOPTOSIS; CELL COUNT; CORNEA; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, CORNEAL; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NECROSIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33750713389     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.377     Document Type: Article

References (38)

1. Clark, C.M., and Lee, D.A. Prevention and treatment of the complications of diabetes mellitus. N. Eng. J. Med. 332:1210-1217, 1995.
2. Aiello, L.P., Gardner, T.W., King, G.L., et al. Diabetic retinopathy. Diab. Care 21:143-156, 1998.
3. Feman, S.S. Diabetes and the eye. In Tasman W. (Ed.), Duane's Clinical Ophthalmology, Vol. 5. Philadelphia: Lippincott Williams & Wilkins, 2000:1-10.
4. Herse, P.R. A review of manifestations of diabetes mellitus in the anterior eye and cornea. Am. J. Optom. Physiol. Opt. 65:224-230, 1988.
5. Kaji, Y. Prevention of diabetic keratopathy. Br. J. Ophthalmol. 89:254-255, 2005.
6. Schultz, R.O., Van Horn, D.L., Peters, M.A., et al. Diabetic keratopathy. Trans. Am. Ophthalmol. Soc. 79:180-199, 1981.
7. Sanchez-Thorin, J.C. The cornea in diabetes mellitus. Int. Ophthalmol. Clin. 38:19-36, 1998.
8. Cisarik-Fredenburg, P. Discoveries in research on diabetic keratopathy. Optometry 72:691-704, 2001.
9. Zagon, I.S., Sassani, J.W., and McLaughlin, P.J. Reepithelialization of the human cornea is regulated by endogenous opioids. Invest. Ophthalmol. Vis. Sci. 41:73-81, 2000.
10. Zagon, I.S., Sassani, J.W., and McLaughlin, P.J. Reepithelialization of the rat cornea is accelerated by blockade of opioid receptors. Brain Res. 798:254-260, 1998.
11. Zagon, I.S., Sassani, J.W., and McLaughlin, P.J. Reepithelialization of the rabbit cornea is regulated by opioid growth factor. Brain Res. 803:61-68, 1998.
12. Zagon, I.S., Jenkins, J.B., Sassani, J.W., et al. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat. Diabetes 51:3055-3062, 2002.
13. Zagon, I.S., Verderame, M.F., and McLaughlin, P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res. Rev. 38:351-376, 2002.
14. Cheng, F., Zagon, I.S., Verderame, M.F., and McLaughlin, P.J. OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous-cell carcinoma of the head and neck [abstr. #2081]. Am. Assoc. Cancer Res. 97th Annual Meeting: Washington, D.C., April 1-5, 2006.
15. Cheng, F., Verderame, M.F., McLaughlin, P.J., and Zagon, I.F. Inhibition of pancreatic cancer through the OGF-OGFr axis is mediated by the cyclin-dependent kinase inhibitor p21 [abstr. #2077]. Am. Assoc. Cancer Res. 97th Annual Meeting: Washington, D.C., April 1-5, 2006.
16. Zagon, I.S., Sassani, J.W., and McLaughlin, P.J. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone. Cornea in press, 2006.
17. Zagon, I.S., Sassani, J.W., and McLaughlin, P.J. Insulin treatment ameliorates impaired corneal reepithelialization in diabetic rats. Diabetes 85:1141-1147, 2006.
18. Havel, P.J., Hahn, T.M., Sindelar, D.K., et al. Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 49:244-252, 2000.
19. Ahren, B., Stern, J.S., Gingerich, R.L., et al. Glucagon secretory responses to hypoglycemia, adrenaline, and carbachol in streptozotocin diabetic rats. Acta. Physiol. Scand. 155:215-221, 1995.
20. Nakamura, M., Sato, N., Chikama, T.-I., et al. Fibronectin facilitates corneal epithelial wound healing in diabetic rats. Exp. Eye Res. 64:355-359, 1997.
21. Tuft, S.J., Williams, K.A., and Coster, D.J. Endothelial repair in the rat cornea. Invest. Ophthalmol. Vis. Sci. 27:1199-1204, 1986.
22. Murphy, P.J., Patel, S., Kong, N., et al. Noninvasive assessment of corneal sensitivity in young and elderly diabetic and nondiabetic subjects. Invest. Ophthalmol. Vis. Sci. 45:1737-1742, 2004.
23. Saito, J., Enoki, M., Hara, M., et al. Correlation of corneal sensation, but not of basal or reflex tear secretion, with the stage of diabetic retinopathy. Cornea 22:15-18, 2003.
24. Kaiserman, I., Kaiserman, N., Nakar, S., et al. Dry eye in diabetic patients. Am. J. Ophthalmol. 139:498-503, 2005.
25. Seifart, U., and Strempel, I. The dry eye and diabetes mellitus. Ophthalmologe 91:235-239, 1994.
26. Nepp, J., Abela, C., Polzer, I., et al. Is there a correlation between the severity of diabetic retinopathy and keratoconjunctivitis sicca? Cornea 19:487-489, 2000.
27. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Eng. J. Med. 329:977-986, 1993.
28. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Eng. J. Med. 353:2643-2653, 2005.
29. Muller, L.J., Marfurt, C.F., Kruse, F., et al. Corneal nerves: Structure, contents and function. Exp. Eye Res. 76:521-542, 2003.
30. Malik, R.A., Kallinikos, P., Abbott, C.A., et al. Corneal confocal microscopy: A noninvasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 46:683-688, 2003.
31. Rosenberg, M.E., Tervo, T.M.T., Immonen, I.J., et al. Corneal structure and sensitivity in Type 1 diabetes mellitus. Invest. Ophthalmol. Vis. Sci. 41:2915-2921, 2000.
32. Fallucca, F., Tonnarini, G., Di Biase, N., et al. Plasma met-enkephalin levels in diabetic patients: Influence of autonomic neuropathy. Metabolism 45:1065-1068, 1996.
33. Negri, M., Tonnarini, G., D'Alessandro, M., et al. Plasma met-enkephalin in Type 1 diabetes. Metabolism 41:460-461, 1992.
34. Wenk, H.N., Nannenga, M.N., and Honda, C.N. Effect of morphine sulphate eye drops on hyperalgesia in the rat cornea. Pain 105:455-465, 2003.
35. Robertson, S.A., and Andrew, S.E. Presence of opioid growth factor and its receptor in the normal dog, cat, and horse cornea. Vet. Ophthalmol. 6:131-134, 2003.
36. Stiles, J., Honda, C.N., Krohne, S.G., et al. Effect of topical administration of 1% morphine sulfate solution on signs of pain and corneal wound healing in dogs. Am. J. Vet. Res. 64:813-818, 2003.
37. Starck, T., Hersh, P.S., and Kenyon, K.R. Corneal dysgenesis, dystrophies, and degenerations. In: Albert D.M., Jakobiec P.A., Azar D.T., Gragoudas E.S. (Eds.), Principles and Practice of Ophthalmology, Vol. 2 (2nd ed.), Philadelphia: Saunders, 2000:2695-2755.
38. Smolin, G., and Thoft, R.A. (Eds.), The Cornea. (3rd ed.). Boston: Little, Brown and Company, 1994.